Cristina Oliva

Cristina is a board-certified medical oncologist with over 20 years’ experience in oncology drug development across large and mid-size pharmaceutical, biotechnology and Clinical Research Organizations.

In her extensive and global experience in drug development from early to late stage, she successfully led several oncology and onco-haematology compounds to the regulatory approval.

Cristina held senior positions leading oncology development programs for Nordic Nanovector, Shionogi, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly and most recently was the Vice-President and Head of the Oncology Centre of Excellence at IQVIA.

Cristina graduated as MD at the University of Genoa (Italy) where she also obtained her oncology board certification.

Cristina joined BerGenBio as Chief Medical Officer in 2022 and is the medical and clinical lead of all BerGenBio clinical development activities.